Welcome to our dedicated page for Lifevantage SEC filings (Ticker: LFVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LifeVantage Corporation (Nasdaq: LFVN) is a Delaware-incorporated health and wellness company that focuses on nutrigenomics and cellular activation, and its SEC filings provide detailed insight into its operations, governance, and financial performance. As a public company, LifeVantage files annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and proxy statements on Schedule 14A, among other documents.
Through these filings, investors can review information about LifeVantage’s activator-based product portfolio, which includes the Protandim family, TrueScience Liquid Collagen, the MindBody GLP-1 System, P84, AXIO nootropic energy drink mixes, activation-supporting nutrients, the TrueScience skin and hair care line, and Petandim. The filings also describe the company’s direct selling model, under which independent Consultants sell products to Customers and share the business opportunity with entrepreneurs.
Current reports on Form 8-K document material events such as financial results announcements, executive officer changes, and other significant corporate developments. Definitive proxy statements (DEF 14A) provide detail on board composition, executive compensation, equity incentive plans like the 2017 Long-Term Incentive Plan, and matters submitted to stockholder votes, including director elections, say-on-pay proposals, and auditor ratification. Voting results for these proposals are also reported in 8-K filings.
On this page, LifeVantage filings are updated as they are made available through the EDGAR system. AI-powered tools summarize key sections of lengthy documents, helping readers understand topics such as revenue trends, non-GAAP measures like adjusted EBITDA and adjusted earnings per share, stock-based compensation plans, and governance structures without reading every line. Users can also review disclosures related to dividends, share repurchases, and risk factors referenced in the company’s periodic reports.
For those researching LFVN, this filings archive offers a structured view of LifeVantage’s regulatory history, financial reporting, and corporate decision-making, with AI-generated highlights to make complex filings more accessible.
Darwin Lewis, a director of Lifevantage Corp (LFVN), reported an automatic purchase of common stock under a Rule 10b5-1 trading plan. On 09/16/2025 he acquired 450 shares at a price of $10.8499 per share, bringing his total beneficial ownership to 117,217 shares. The filing states the 10b5-1 plan was adopted on February 10, 2025. The Form 4 was signed on behalf of Mr. Lewis by a power of attorney on 09/18/2025. The report lists the transaction as a non-derivative acquisition and identifies Mr. Lewis as a director of the issuer.
Lifevantage Corp (LFVN) director Michael A. Beindorff reported insider sales on 09/09/2025. The Form 4 shows two open-market dispositions: 4,125 shares sold at $11.44 and 200 shares sold at $11.35. After these transactions, the filing reports 22,858 shares held directly by Mr. Beindorff and indirect holdings that include 126 shares held by spouse as custodian for minor children, 91,413 shares held by a trust, and 5,500 shares held indirectly by spouse. The filing notes the trust is the Michael A. Beindorff Trust dated 06/14/2000, of which the reporting person and his spouse are trustees.
LifeVantage Corporation disclosed that on September 4, 2025 it issued a press release announcing its financial results for the fourth quarter and full fiscal year ended June 30, 2025. The press release is included as Exhibit 99.1 to the current report. The filing notes the furnished information is not being deemed "filed" under the Exchange Act and therefore is not subject to the liabilities of Section 18.
LifeVantage Corporation describes its direct-selling dietary supplement and personal-care business, emphasizing a nutrigenomics "activating wellness" strategy and product portfolio including Protandim4, TrueScience4 skin and hair care, AXIO4 energy drinks, Petandim4, and the patent-pending MindBody GLP-1 System42; MB Core42; MB Enhance42. The company reported approximately $220.0 million aggregate market value of common stock held by non-affiliates as of December 31, 2024 and 12,691,009 shares outstanding as of September 3, 2025. As of June 30, 2025 it employed 238 people and had ~51,000 active independent consultants (vs 49,000 in fiscal 2024). Approximately 22% of fiscal 2025 revenue was international, primarily Japan. There was no outstanding balance on the 2024 Credit Facility as of June 30, 2025; the facility matures April 12, 2027. The filing lists material risks including dependence on independent consultants, concentration on a few products, third-party manufacturing and supply-chain risks, regulatory and advertising scrutiny, cybersecurity and data-privacy obligations, potential tax or employment classification exposure for consultants, activist stockholder actions, and foreign currency and market-entry risks.
The Form 4 filed for LifeVantage Corp (LFVN) reports insider activity by CFO Carl Aure. On 08/31/2025 Mr. Aure had 14,792 and 18,886 Performance Restricted Stock Units (PRSUs) marked as acquired (codes M) that convert one-for-one into common stock when vesting criteria are met, and the filing notes those PRSUs were originally granted in 2023 and 2024. The report also reflects 718 shares purchased under the Employee Stock Purchase Plan, and a disposition of 16,610 shares sold at $13.10 per share. Following the transactions, the filing shows total beneficial ownership figures reported per line items.
Kristen Cunningham, Chief Sales Officer of LifeVantage Corp (LFVN), reported changes in her beneficial ownership on a Form 4 covering transactions dated 08/31/2025. The filing shows conversion/acquisition of 17,752 and 26,150 performance restricted stock units (PRSUs) into common stock at no cash price, an ESPP purchase of 254 shares, and a sale of 21,801 common shares at $13.10 per share. After the transactions, reported beneficial ownership totals shown range between 134,357 and 160,507 shares depending on which line is referenced; derivative holdings converted on a one-for-one basis into common stock.
Steven R. Fife, President and CEO and director of Lifevantage Corp (LFVN), reported insider transactions on 08/31/2025. Two tranches of previously granted performance restricted stock units converted into common stock: 90,718 shares (granted 08/24/2023) and 108,960 shares (granted 08/26/2024). Those PRSUs convert one-for-one into common shares and were reported as acquired at $0 under Rule 16 reporting codes. Separately, 98,177 shares were disposed of at a reported price of $13.10, leaving the reporting person with 761,001 and 859,178 total shares following the respective transactions as shown on the form.
Lifevantage Corp (LFVN) reporting person Alissa Neufeld recorded equity activity consisting of performance restricted stock units (PRSUs) and a disposition of common stock. The filing shows PRSUs granted in 2023 and 2024 that convert one-for-one into common stock, two grant-related transactions adding 14,498 and 18,886 shares (Transaction Code M) at $0 per share, and a sale (Transaction Code F) of 15,729 shares at $13.10 per share. After these transactions the reporting person beneficially owned 118,260 common shares.
The derivative section shows the PRSUs underlying 14,498 and 18,886 units, with post-transaction derivative beneficial ownership reported as 4,832 and 9,443 respectively. The filing states the PRSUs vest upon meeting pre-established time-based and financial performance criteria and convert into common stock on a one-for-one basis.
Julie Boyster, identified as an Officer (Chief Marketing Officer), reported Section 16 transactions in Lifevantage Corp (LFVN) on 08/31/2025. Two grants of Performance Restricted Stock Units (PRSUs) converted or vested resulting in acquisitions: 18,934 shares (from a PRSU grant on 08/24/2023) and 27,966 shares (from a PRSU grant on 08/26/2024). The filing states PRSUs convert into common stock on a one-for-one basis. The holder also reported a disposition of 23,293 shares at a price of $13.10 each. Following the reported transactions, the form shows the reporting person beneficially owned 151,923 shares directly. The form is signed by a power of attorney on behalf of Julie Boyster.
Alissa Neufeld, General Counsel of Lifevantage Corp (LFVN), received equity awards on 08/26/2025. The Form 4 shows an award of 9,036 stock units and 13,554 Performance Restricted Stock Units (PRSUs). After the grant, Ms. Neufeld beneficially owns 100,605 shares of common stock and 13,554 PRSU equivalents. The stock units vest with 5/12 of the award on September 10, 2026 and the remainder in equal installments on the tenth day of the third month of each of seven subsequent calendar quarters. The PRSUs vest only if performance targets are met (target payout shown); upon maximum performance the award may pay up to 200% of target, with vested portions scheduled 34% on Sept 10, 2026, 33% on Sept 10, 2027, and 33% on Sept 10, 2028.